The Hologic, Inc. (HOLX) Receives Average Rating of “Buy” from Analysts

The Hologic, Inc. (HOLX) Receives Average Rating of “Buy” from Analysts

Several equities research analysts recently issued reports on HOLX shares. Zacks Investment Research upgraded Hologic from a “sell” rating to a “strong-buy” rating and set a $49.00 price objective on the stock in a report on Tuesday, April 4th. Barclays PLC set a $50.00 price objective on Hologic and gave the company a “buy” rating in a report on Wednesday, April 5th. Stifel Nicolaus boosted their price objective on Hologic from $45.00 to $48.00 and gave the company a “buy” rating in a report on Thursday, May 11th. Canaccord Genuity reiterated a “buy” rating and issued a $53.00 price objective on shares of Hologic in a report on Tuesday, May 9th. Finally, BTIG Research reiterated a “buy” rating and issued a $47.00 price objective on shares of Hologic in a report on Sunday, May 14th.

Hologic, Inc. (NASDAQ:HOLX) has been assigned an average recommendation of “Buy” from the fourteen ratings firms that are covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and nine have given a buy rating to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $47.67.

Hologic (NASDAQ:HOLX) opened at 45.13 on Tuesday. Hologic has a 52 week low of $35.15 and a 52 week high of $46.80. The stock has a market cap of $12.64 billion, a price-to-earnings ratio of 16.18 and a beta of 0.91. The stock’s 50 day moving average price is $45.10 and its 200 day moving average price is $42.80.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Wednesday, May 10th. The medical equipment provider reported $0.50 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.46 by $0.04. The firm had revenue of $715.40 million for the quarter, compared to the consensus estimate of $685.24 million. Hologic had a return on equity of 25.26% and a net margin of 27.31%. The company’s quarterly revenue was up 3.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.47 EPS. On average, analysts forecast that Hologic will post $2.01 earnings per share for the current year.

In other Hologic news, Director Elaine Ullian sold 8,938 shares of the company’s stock in a transaction dated Friday, June 2nd. The stock was sold at an average price of $43.99, for a total transaction of $393,182.62. Following the sale, the director now owns 23,810 shares in the company, valued at approximately $1,047,401.90. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Lawrence M. Levy sold 10,203 shares of the company’s stock in a transaction dated Wednesday, May 3rd. The stock was sold at an average price of $45.00, for a total value of $459,135.00. Following the sale, the director now owns 38,832 shares in the company, valued at approximately $1,747,440. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 84,139 shares of company stock worth $3,722,376. 0.79% of the stock is owned by company insiders.

A number of large investors have recently modified their holdings of the company. UBS Asset Management Americas Inc. increased its position in Hologic by 123.2% in the fourth quarter. UBS Asset Management Americas Inc. now owns 1,446,445 shares of the medical equipment provider’s stock worth $58,032,000 after buying an additional 798,541 shares during the last quarter. Whalerock Point Partners LLC increased its position in Hologic by 57.4% in the fourth quarter. Whalerock Point Partners LLC now owns 37,850 shares of the medical equipment provider’s stock worth $1,519,000 after buying an additional 13,800 shares during the last quarter. Teachers Advisors LLC increased its position in Hologic by 28.8% in the fourth quarter. Teachers Advisors LLC now owns 643,547 shares of the medical equipment provider’s stock worth $25,819,000 after buying an additional 143,960 shares during the last quarter. Kentucky Retirement Systems acquired a new position in Hologic during the fourth quarter worth approximately $810,000. Finally, Kentucky Retirement Systems Insurance Trust Fund acquired a new position in Hologic during the fourth quarter worth approximately $361,000. Institutional investors own 94.09% of the company’s stock.

About Hologic

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Related posts

Leave a Comment